Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in High-Risk Former-Smokers
NCT06038526Phase 2Completed
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in lung cancer. Started Mar 2024; status: completed.
02
Drugs
canakinumab
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06038526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038526.